Your Search Results

New platforms for coronary lesions treatment

21 May 2026 – From EuroPCR 2026

Delve into the latest developments in coronary lesion treatment platforms through this session, highlighting real-world performance data of novel drug-eluting stents like Eternia and Evermine 50. It also presents preclinical insights on biomimetic CD31-coated stents, long-term outcomes of the Fantom BRS platform, and innovative randomized trials...

Left main complications - Part 2

21 May 2026 – From EuroPCR 2026

This session covers intricate complications involving the left main coronary artery (LMCA), highlighting cases of catheter-induced dissections, challenges in chronic total occlusion (CTO) PCI, and rare scenarios such as stent entrapment and complex re-interventions. Emphasis is placed on the critical utility of intravascular ultrasound (IVUS) and...

Risk stratification and reperfusion strategies for acute and subacute pulmonary embolism

21 May 2026 – From EuroPCR 2026

Focus on risk stratification and reperfusion strategies for acute and subacute pulmonary embolism through this session. It discusses the impact of elective endovascular therapies in intermediate-high risk patients, intraprocedural complications, and early mortality associated with catheter interventions. Additionally, it reviews real-world outcomes of catheter-directed therapy, national...

Imaging-guided calcified lesion PCI

21 May 2026 – From EuroPCR 2026

This session presents state-of-the-art imaging-guided interventions for calcified coronary lesions, showcasing modalities such as lithotripsy, rotational atherectomy, and complex calcium modification techniques. It includes case studies highlighting zero-contrast PCI and stenting in challenging anatomies, including left main bifurcation lesions in elderly patients with complex clinical backgrounds.

CTO PCI: understand it, love it

21 May 2026 – From EuroPCR 2026

This educational session provides a comprehensive overview of chronic total occlusion (CTO) PCI, elucidating key procedural steps, essential materials, and potential complications. It highlights the significant role of nurses and allied health professionals in supporting the procedure and enhancing patient experience throughout the pre-, intra-, and...

Percutaneous management of mitral and aortic valve disease

21 May 2026 – From EuroPCR 2026

Delve into the percutaneous management of mitral and aortic valve disease through detailed procedural demonstrations. This session covers valve-in-valve procedures, navigation of potential complications in valve-in-valve TAVI, and mitral valve edge-to-edge repair techniques, supported by real-world case discussions and key learnings.

Refining the gold standard: what is new in DES

21 May 2026 – From EuroPCR 2026

This session explores recent advancements in drug-eluting stent (DES) technology, featuring global real-world evidence on short dual antiplatelet therapy (DAPT) with polymer-free DES, angiographic outcomes from pooled TARGET trials, and real-world registry data on various DES platforms. It also presents post-marketing surveillance results and systematic reviews...

Complex multivessel disease: from calcium to physiology - Case-based decisions

21 May 2026 – From EuroPCR 2026

Focus on complex multivessel coronary artery disease management with an emphasis on severely calcified lesions and the integration of intracoronary imaging and physiology. This session prepares clinicians to anticipate and manage complications during PCI, enhancing competence in treating challenging coronary anatomies through case-based decision-making.

MASTER-DAPT: “the MASTER of high-bleeding risk trials”

28 Aug 2021

Marco Valgimigli (Lugano, Switzerland) presented the results of the MASTER DAPT trial on Saturday, August 28, in a Hot Line session of the ESC Congress 2021. Luis G. Ortega-Paz provides his PICOT & SWOT analysis of this study.

Author

Luis Ortega-Paz

ESC Congress 2021 - MASTER-DAPT : “the MASTER of high-bleeding risk trials”

On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial

05 Mar 2023

Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Author

Mirvat Alasnag

$On-site computed tomography-derived fractional flow reserve to guide the management of patients with stable coronary artery disease: The TARGET randomized trial$

SMT’s Hydra TAVR Valve demonstrates sustained safety, durability, and hemodynamic performance at 5 Years

19 Nov 2025

TRISCEND II trial: Randomized comparison of transcatheter valve replacement vs. optimal medical therapy for severe tricuspid regurgitation

04 Nov 2024

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali